All In Biotech

Drug Trial Radar · NCT07695740

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

A Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Dec 2027

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 clinical trial is to learn whether YKST02 is effective and safe in adults with relapsed or refractory multiple myeloma. The study will also evaluate how YKST02 is processed by the body (pharmacokinetics), how it affects the body (pharmacodynamics), and whether it causes the body to produce anti-drug antibodies. The main questions it aims to answer are: Does YKST02 demonstrate clinical efficacy in adults with relapsed or refractory multiple myeloma? What side effects occur during treatment with YKST02? What are the pharmacokinetic, pharmacodynamic, and immunogenicity characteristics of YKST02? Participants will: Complete screening assessments to determine whether they are eligible for the study. Receive YKST02 by intravenous infusion according to the study treatment schedule. Undergo regular assessments to evaluate treatment response and monitor safety. Provide blood and urine samples for pharmacokinetic, pharmacodynamic, and immunogenicity testing. Complete follow-up visits after treatment discontinuation to monitor disease progression and survival. Multiple myeloma is a cancer of plasma cells that remains incurable despite advances in treatment. Although currently available therapies can improve outcomes, most patients eventually experience disease relapse or become refractory to treatment. YKST02 is an investigational humanized bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells. Simultaneous binding to BCMA and CD3 may activate T cells and promote tumor cell killing. This is a multicenter, open-label study consisting of two parts (Phase IIa and Phase IIb). In Phase IIa, participants will initially receive YKST02 at the starting dose level. Safety and efficacy data from this part of the study will be reviewed to determine the dose to be evaluated in Phase IIb.

Conditions

  • Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions

  • YKST02Drug

    Participants will receive YKST02 by intravenous infusion according to the protocol-defined treatment schedule. Treatment will continue until a protocol-defined treatment discontinuation criterion is met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From first dose until disease progression or initiation of subsequent anti-cancer therapy, whichever occurs first (up to approximately 2 years).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.